10x Genomics (TXG) EBT Margin (2018 - 2026)

10x Genomics (TXG) posted EBT Margin of 8.52% for Q1 2026, up 6.93% sequentially from 9.15% in Q4 2025, and up 1312.0% YoY from 0.6% in Q1 2025.

10x Genomics (TXG) EBT Margin (2018 - 2026) Analysis & Trends

10x Genomics has reported EBT Margin for 9 years, with the latest figure at 8.52% in Q1 2026.

Quarterly EBT Margin rose 1312.0% year-over-year to 8.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 3.01% (up 2154.0% YoY) and the FY2025 annual result came in at 6.21%, up 2289.0% from the prior year.
EBT Margin advanced to 8.52% in Q1 2026 per TXG's latest filing, from 9.15% in the prior quarter.
Over five years, EBT Margin peaked at 21.4% in Q2 2025 and troughed at 59.71% in Q3 2023.
A 5-year average of 26.51% and a median of 25.33% in 2023 frame the typical range for EBT Margin.
The sharpest annual moves came in 2022 and 2025: EBT Margin sank 4710 bps in 2022, then jumped 4562 bps in 2025.
Over 5 years, EBT Margin stood at 10.5% in 2022, then plunged by 141 bps to 25.33% in 2023, then retreated by 16 bps to 29.32% in 2024, then soared by 69 bps to 9.15% in 2025, then rose by 7 bps to 8.52% in 2026.
According to Business Quant data, EBT Margin over the past three periods registered 8.52%, 9.15%, and 18.93% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Veeva Systems	39.72 Bn	32.40 Bn	662.02 Mn	39.36%
2	BrightSpring Health Services	12.19 Bn	11.64 Bn	492.75 Mn	2.41%
3	Healthequity	8.79 Bn	8.52 Bn	256.31 Mn	26.06%
4	10x Genomics	7.31 Bn	6.76 Bn	112.50 Mn	-12.34%
5	Hinge Health	7.10 Bn	6.71 Bn	183.95 Mn	20.88%
6	MiniMed	5.66 Bn	5.36 Bn	480.00 Mn	-10.99%
7	Waystar Holding	4.76 Bn	4.56 Bn	221.99 Mn	17.64%
8	Doximity	4.46 Bn	3.77 Bn	132.93 Mn	25.77%
9	Heartflow	3.66 Bn	3.28 Bn	53.19 Mn	-24.53%
10	Privia Health	2.78 Bn	2.42 Bn	-	2.65%

Download Data